GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (TSE:4519) » Definitions » Net Current Asset Value

Chugai Pharmaceutical Co (TSE:4519) Net Current Asset Value : 円709.56 (As of Jun. 2024)


View and export this data going back to 1956. Start your Free Trial

What is Chugai Pharmaceutical Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Chugai Pharmaceutical Co's net current asset value per share for the quarter that ended in Jun. 2024 was 円709.56.

The historical rank and industry rank for Chugai Pharmaceutical Co's Net Current Asset Value or its related term are showing as below:

TSE:4519' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.09   Med: 7.36   Max: 17.89
Current: 9.29

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Chugai Pharmaceutical Co was 17.89. The lowest was 4.09. And the median was 7.36.

TSE:4519's Price-to-Net-Current-Asset-Value is ranked worse than
65.79% of 611 companies
in the Drug Manufacturers industry
Industry Median: 5.72 vs TSE:4519: 9.29

Chugai Pharmaceutical Co Net Current Asset Value Historical Data

The historical data trend for Chugai Pharmaceutical Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Net Current Asset Value Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 301.20 352.47 433.60 541.97 643.93

Chugai Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 592.54 643.93 647.96 709.56 -

Competitive Comparison of Chugai Pharmaceutical Co's Net Current Asset Value

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Price-to-Net-Current-Asset-Value falls into.



Chugai Pharmaceutical Co Net Current Asset Value Calculation

Chugai Pharmaceutical Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1366426-306967-0-0)/1645.31
=643.93

Chugai Pharmaceutical Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1476031-308472-0-0)/1645.47
=709.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co  (TSE:4519) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Chugai Pharmaceutical Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.

Chugai Pharmaceutical Co Headlines

No Headlines